Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,021 to 1,040 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Randomized Sibutramine vs Randomized Placebo: Risk of Death From Any Cause (All-cause Mortality) | 418 of 4,906 404 of 4,898 | 0.3 points -0.8 to 1.4 | 9,804 | NCT00234832 A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
| Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE | 11 of 4,906 7 of 4,898 | 0.1 points -0.1 to 0.3 | 9,804 | NCT00234832 A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
| Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a POE or a Revascularization Procedure | 927 of 4,906 856 of 4,898 | 1.4 points -0.1 to 2.9 | 9,804 | NCT00234832 A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
| Vitamins vs Placebo: Admission to NICU | 577 of 4,900 557 of 4,881 | 0.4 points -0.9 to 1.6 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Small for Gestational Age | 133 of 4,900 132 of 4,881 | 0.0 points -0.6 to 0.7 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Birth Weight <2500 Grams | 345 of 4,900 369 of 4,881 | -0.5 points -1.6 to 0.5 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Respiratory Distress Syndrome | 150 of 4,900 144 of 4,881 | 0.1 points -0.6 to 0.8 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Retinopathy of Prematurity | 19 of 4,900 16 of 4,881 | 0.1 points -0.2 to 0.3 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Apgar Score <=3 at 5 Minutes | 23 of 4,900 27 of 4,881 | -0.1 points -0.4 to 0.2 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Sepsis | 30 of 4,900 23 of 4,881 | 0.1 points -0.2 to 0.4 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Necrotizing Enterocolitis | 10 of 4,900 14 of 4,881 | -0.1 points -0.3 to 0.1 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Intraventricular Hemorrhage, Grade III or IV | 6 of 4,900 7 of 4,881 | -0.0 points -0.2 to 0.1 | 9,781 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Xylitol vs Control: Number of Infants With Adverse Neonatal Composite Morbidity and Mortality | 133 of 4,349 238 of 5,321 | -1.4 points -2.2 to -0.7 | 9,670 | NCT02333227 Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi |
| Xylitol vs Control: Rate of Preterm Birth | 549 of 4,349 878 of 5,321 | -3.9 points -5.3 to -2.5 | 9,670 | NCT02333227 Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi |
| Tamoxifen Followed by Exemestane vs Exemestane: serious adverse events | 784 of 4,814 831 of 4,852 | -0.8 points -2.3 to 0.6 | 9,666 | NCT00036270 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane |
| Oral Semaglutide vs Placebo: Number of Participants From Randomization to First Occurrence of CV Death;Renal Death;Onset of Persistent≥50% Reduction in eGFR(CKD-EPI);Onset of Persistent eGFR(CKD-EPI)<15 mL/Min/1.73m^2;Initiation of Chronic Renal Replacement Therapy | 403 of 4,825 435 of 4,825 | -0.7 points -1.8 to 0.5 | 9,650 | NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Number of Participants From Randomization to First Occurrence of Major Adverse Limb Events (MALE), a Composite Endpoint Consisting of: Acute Limb Ischemia Hospitalisation/Chronic Limb Ischemia Hospitalisation | 71 of 4,825 99 of 4,825 | -0.6 points -1.1 to -0.1 | 9,650 | NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Number of Participants From Randomisation to First Occurrence of Onset of Persistent eGFR (CKD-EPI) Below 15 mL/Min/1.73 m^2 | 23 of 4,825 33 of 4,825 | -0.2 points -0.5 to 0.1 | 9,650 | NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Number of Participants From Randomisation to First Occurrence of Non-fatal Myocardial Infarction (MI) | 191 of 4,825 253 of 4,825 | -1.3 points -2.1 to -0.4 | 9,650 | NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes |
| Oral Semaglutide vs Placebo: Number of Participants From Randomisation to Time to Occurrence of Renal Death | 1 of 4,825 7 of 4,825 | -0.1 points -0.3 to -0.0 | 9,650 | NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=52
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00234832-2f5415ed",
"title": "Randomized Sibutramine vs Randomized Placebo: Risk of Death From Any Cause (All-cause Mortality)",
"summary": "418 of 4906 against 404 of 4898; risk difference 0.3 points, 95% interval -0.8 to 1.4; NCT00234832, A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients",
"record": "/library/comparisons/NCT00234832-2f5415ed",
"nct_id": "NCT00234832",
"kind": "outcome",
"participants": 9804,
"risk_difference": {
"value": 0.002719147744022904,
"lower": -0.008266574108377106,
"upper": 0.013707500572164159
},
"group_1": "418 of 4,906",
"group_2": "404 of 4,898",
"difference": "0.3 points",
"interval": "-0.8 to 1.4",
"trial_title": "A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients"
},
{
"id": "NCT00234832-8cc22a69",
"title": "Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE",
"summary": "11 of 4906 against 7 of 4898; risk difference 0.1 points, 95% interval -0.1 to 0.3; NCT00234832, A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients",
"record": "/library/comparisons/NCT00234832-8cc22a69",
"nct_id": "NCT00234832",
"kind": "outcome",
"participants": 9804,
"risk_difference": {
"value": 0.0008129977093240216,
"lower": -0.0009992351119284368,
"upper": 0.002728870561461914
},
"group_1": "11 of 4,906",
"group_2": "7 of 4,898",
"difference": "0.1 points",
"interval": "-0.1 to 0.3",
"trial_title": "A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=53",
"request_id": "4-K_CPHpIl0QaWwN"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant